Vland Ranks No.177 on the List of China's Top 500 Patent Enterprises, Leading the Chinese Biotech Industry

On July 23, 2019, co-organized by the Chinese Scholars Marketing Association, Guangdong Enterprise Brand Construction and Promotion Association, National Brand and Innovation (Guangzhou) Base as well as Hengqin Intellectual Property Exchange, China International Marketing Conference 2019 and China Creation Forum were held in Guangzhou, China.

In this event, the list of China's top 500 patent enterprises was released for the first time after the evaluation of 9 indicators through AI plus Big Data Analysis method. Huawei Technologies Co.,Ltd., Beijing Zhigu Ruituo Technical Service Co., Ltd., and Shenzhen BTR New Energy Materials Co., Ltd. were among the top three on the list.

China's Top 500 Patent Enterprises

Qingdao Vland Biotech Group

No.177

Leader in Biotech Field

As of the first half of 2019, Vland Biotech Group and its subsidiaries own 222 Chinese authorized invention patents, 4 US authorized patents, 11 PCT international applications, and 34 new veterinary drug registration certificates (including 3 national first-class veterinary drugs).

Vland, guided by market demand, stays committed to the strategy of technology-driven development. Adopting a R&D model with independent R&D as the core and cooperative R&D as a supplement, it continues to increase investments and development efforts in new products, thus providing continuous technological impetus for the sustainable development. In the first half of 2019, Vland’s R&D investment increased 9.88% from the same period in 2018 to RMB 35.7025 million, accounting for 9.05% of the operating income, which is relatively high in the industry. Among the investment, 13.88% went to the R&D of enzymes, comparable to those internationally renowned enzyme companies.